Geneoscopy

Live with Labcorp!
We are incredibly proud to celebrate the nationwide launch of ColoSense® through our commercial collaboration with Labcorp!

This milestone follows a wave of incredible clinical and regulatory validation for our advanced RNA technology. ColoSense is now included as a recommended option in both the American Cancer Society(ACS) and National Comprehensive Cancer Network (NCCN) screening guidelines, and is covered for eligible Medicare beneficiaries following the recent Center for Medicare and Medicaid Services (CMS) National Coverage Determination update.

By bringing this highly endorsed test to Labcorp’s extensive nationwide network, we are delivering a simplified, scrape-free collection experience explicitly designed to overcome common patient barriers and improve compliance. Together, we are making early detection more reliable, approachable, and widely accessible.

🔗 Read the full joint announcement here: https://www.prnewswire.com/news-releases/labcorp-announces-nationwide-availability-of-colosense-the-first-fda-approved-rna-based-at-home-colorectal-cancer-screening-test-302806130.html

Labcorp Announces Nationwide Availability of ColoSense®, the First FDA-Approved RNA-Based At-Home Colorectal Cancer Screening Test /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the nationwide availability of...

At Geneoscopy, our commitment to innovation is fueled not only by our experienced team members but also by our talented interns, who bring fresh perspectives and enthusiasm.

Today, we’re excited to spotlight two of our new interns: Abby Finnegan from the Clinical Studies department and Cecelia Kraeger from the Medical department, both working at our St. Louis headquarters.

We spoke with Abby to learn more about her background and experiences:
What was your major, and where did you study?
I graduated with a degree in political science from Hope College in 2021!

What initially attracted you to apply for an internship at Geneoscopy?
I love Dr. Erica and the work she does, and when the opportunity came to apply for an internship here, I knew I had to jump on it!

How do you spend your time outside of work?
I usually hang out with my dogs and my boyfriend, and I play viola and lots of video games!

Next, we caught up with Cecelia to hear about her journey from school to her Summer with Geneoscopy:
What is your academic focus, and where are you studying?
I will be a senior at Texas Christian University, majoring in Biology and minoring in Studio Art. I am currently on the pre-med track.

What motivated you to choose Geneoscopy for your internship?
I have known Erica since I was younger, and I never would have imagined she would one day become my boss! Since then, I have always looked up to and admired her. Geneoscopy stood out to me as a company that’s tackling important healthcare challenges in innovative ways, and I feel so lucky to contribute!

What do you enjoy doing in your spare time?
Outside of work, I love spending quality time with my friends now that we are all home for the summer! I also paint custom designs for friends and family and spend hours in the ceramic studio during the school year. Other than that, you can probably find me in the kitchen cooking!

Both Abby and Cecelia exemplify the passion that drives Geneoscopy forward. If their stories inspire you, and you want to be part of a team that is revolutionizing healthcare, check out our open roles at geneoscopy.com/careers.

We are thrilled to announce that the Centers for Medicare & Medicaid Services (CMS) has approved national coverage for ColoSense®, making it accessible to approximately 65 million eligible Medicare beneficiaries. This milestone marks a major step forward, aligning CMS coverage with recent ACS and NCCN guidelines to establish ColoSense as a preferred, noninvasive screening option.
As the first FDA-approved stool-based RNA test, ColoSense directly addresses a major barrier to at-home screening by eliminating the need for patients to complete the stool scraping or complex sample manipulation. Given that more than half of all colorectal cancer diagnoses still occur in individuals aged 65 and older, providing this simplified screening method is critical for improving screening completion rates.
"Restructuring the framework to include high-sensitivity tests like ColoSense demonstrates the importance that CMS places on earlier detection through preventive screening," notes CEO Andrew Barnell.
A strategic collaboration with Labcorp will further expand access to ColoSense, enabling broader provider and patient adoption through Labcorp’s nationwide network.
🔗 Read our full press release to learn more about this landmark coverage decision: https://www.businesswire.com/news/home/20260605649071/en/CMS-Grants-Medicare-Coverage-for-ColoSense-Expanding-Access-to-Simplified-Noninvasive-Colorectal-Cancer-Screening

Stronger Together, The Geneoscopy Team Onsite

What an incredible week! We brought our entire team together at our St. Louis headquarters for an energizing onsite filled with collaboration, alignment, and shared vision. As well as some Top Golf Fun!

The energy from our expanding team was incredible, with everyone coming together and fully engaged. We are more united than ever in our mission to bring approachable, non-invasive screening options to patients and providers nationwide. There is so much momentum ahead for the rest of 2026, and we can’t wait to share what's coming next!

Here to Inspire Future Innovators

Our Co-Founder and Chief Medical Officer, Dr. Erica Barnell, returned to her alma mater, Washington University in St. Louis, to speak with students participating in the School of Medicine's EXPLORE Innovation Pathway!

As a WashU alumna, Erica loved sharing her personal journey from medical student to biotech entrepreneur. She gave the group a behind-the-scenes look at how she helped take Geneoscopy from an initial concept to developing FDA-approved RNA technology.

The future of healthcare innovation is in incredible hands right here in St. Louis!

Our Co-Founder and CMO, Dr. Erica Barnell, was live on Fox 2 yesterday morning giving a sneak peek into her highly anticipated TEDxStLouis talk happening this Saturday!

Dr. Barnell sat down with the StudioSTL team to discuss this year's theme, "Edge of Possible," which spotlights innovative voices in the community. In her upcoming talk, titled "Four Words Between You and Cancer," she will explore how leaning into uncomfortable conversations and breaking down traditional public health barriers can completely transform early disease detection and prevention.

We are incredibly proud to see our home-grown St. Louis innovation taking the stage alongside a phenomenal lineup of regional thought leaders.

📺 Watch her full Fox 2 morning segment here: https://fox2now.com/video/see-the-%e2%80%9cedge-of-possible%e2%80%9d-at-tedx-st-louis/11833044/

🎟️ Want to see her live? Join us this Saturday, May 30th, at the Missouri History Museum! Grab your tickets before they sell out: https://tedxsaintlouis.org/edge-of-possible-2026

Edge of Possible 2026 — TEDxStLouis | An Inclusive and Equitable Community of Thought Leaders Dr. Erica Barnell, MD/PhD is a physician-scientist, entrepreneur, and nationally recognized leader in gastrointestinal diagnostics, working at the intersection of medicine, molecular biology, and preventive health. She trained at Washington University School of Medicine, where she earned both her MD...

A Historic Milestone for Colorectal Cancer Screening

We are proud to announce that the American Cancer Society (ACS) has updated its colorectal cancer screening guidelines to include ColoSense® as a preferred stool-based testing option!

This update marks the first time a noninvasive RNA-based test has been included in ACS screening guidelines for detecting colorectal cancer and advanced adenomas in average-risk adults aged 45 or older. Widely considered a gold standard in oncology and public health, the ACS guidelines are developed by top experts who evaluate only the highest-quality evidence to assess real-world impact.

"ColoSense combines clinical accuracy with a patient-friendly experience and can help identify patients most at risk of cancer progression" notes Andrew Barnell, CEO and co-founder.

To drive broader provider and patient adoption, our strategic collaboration with Labcorp will expand access to ColoSense in the coming months, utilizing Labcorp’s extensive nationwide network to make this advanced screening option widely available.

With 41% of adults aged 45 and older still unscreened, this guideline update is a critical step forward in making accurate, at-home screening approachable and reliable.

Read the full press release here: https://www.businesswire.com/news/home/20260527486679/en

Business Wire The global leader in press release distribution and regulatory disclosure. Public relations and investor relations professionals rely on Business Wire for broad-based and targeted market reach.

More Faces Behind the Science

While our lab team is busy analyzing RNA, our finance team is working behind the scenes to ensure Geneoscopy has the resources to scale our innovations. Today, we’re highlighting John Harry Wagner, a Financial Analyst I at our St. Louis headquarters!

John Harry plays a vital role in keeping our mission moving forward by managing the complex financial data that fuels our growth.

We asked John Harry about his role at Geneoscopy:
What does your day-to-day look like?
I spend lots of time working through procurement, AP, reimbursement, financial reporting and support across all functions of the finance team.

What is the most rewarding part of working at Geneoscopy?
I get to spend time working with intelligent and hard working employees who care about one another and care about the mission.

Why choose Geneoscopy?
As a company Geneoscopy combines good work life balance with high expectations and high growth for their employees. As a provider the Barnells, the management team and Geneoscopy are focused on saving lives as best as we can. Geneoscopy has good people doing good work!

How are you spending your time when you are not at Geneoscopy?
I spend my time playing games with friends, walking my 16 year old cockapoo with my fiancé Sophie (slowly), visiting with my family who live in STL, or playing competitive beach volleyball.

Want to join a team that is changing the future of healthcare? We are hiring! Check out our open roles at geneoscopy.com/careers.

From groundbreaking research to FDA-approved innovation, Dr. Erica Barnell is transforming the future of preventive healthcare. As co-founder and Chief Medical and Science Officer of Geneoscopy, she is helping revolutionize colorectal cancer screening and improving early detection for patients everywhere.

https://www.eventbrite.com/e/edge-of-possible-by-tedxstlouis-tickets-1979125774468?aff=oddtdtcreator

That’s a wrap on !

Our team spent last week in Chicago at the world's premier meeting for GI professionals at Digestive Disease Week. We were thrilled to present our latest research on colorectal cancer screening and IBD diagnostics, showcasing that non-invasive, RNA-based technology is changing the game for patients.

A huge thank you to everyone who stopped by our posters to discuss our findings. Our team left Chicago more motivated than ever to continue our work in expanding access to early, accurate screening.